Abstract:Abstract Abstract 4501 Chronic graft-versus-host disease (GVHD) is a major complication of allogeneous hematopoietic stem cell transplantation, and it is regarded as a type of Th2 disease and seems to be a T-cell-mediated disorder in which immune tolerance to self-antigens is broken. Mesenchymal stem cells (MSCs) are multipotent cells which can extenuate refractory (GVHD) have been recently reported; however, the clinical data on MSC relieves chronic GVHD are generally lacking, and the machanisms remain to be investigated. One area of recent interest and controversy is the role of regulatory T cells (CD4+/CD25high T cells) in chronic GVHD. We examined the lymphocyte subsets and regulatory T cells of patients with refractory chronic GVHD were treated with basic immunosuppression plus MSCs derived from volunteer donors. Between April 2005 and October 2008, 19 patients were treated with their basic immunosuppression plus in vitro expanded bone-marrow-derived MSC as a compassionate treatment for resistant chronic GVHD. The median MSC dose given was 0.6×106/kg per body weight. Flow cytometric analysis was perfromed to analysis lymphocyte composition and activation at the time before MSC infusion(pre-MSC) and 3 months after MSC infusion (post-MSC). The study was approved by the Ethics Committee of the Guangdong General Hospital. All patients and the MSC donors provided written informed consent. In the present study, there were no significant changes in the proportion of T cells, B cells, NK cells and activation in no-response patients between pre-MSC and post-MSC. In the patients with response, the total lymphocyte was greater post-MSC transfusion than pre-MSC transfusion, and the proportion of CD4+ T cells were increased CD+8 T cells were decreased (the P value was 0.001 and 0.018, respectively). However, the proportion of CD4+CD25+ T cell and CD8+CD25+ T cells hadn't significantly changed post-MSC transfusion compared to pre-MSC infusion in patients with response. The T lymphocyte subsets of CD8+CD28+ cells, which are active CTLs that participate transplantation immunity and rejection reaction, were down-regulated when the chronic GVHD improved post-MSC infusion (P=0.023). By contrast, CD8+CD28- cells, which regulate cells to induce immune tolerance and inhibit antibody production and imbalance in the production of Th1 and Th2 cytokines, were increased in patients responsed to MSC infusion (P=0.025), and the ratio of CD8+CD28- cells to CD8+CD28+ was increased. Importantly, the increase of CD8+CD28- T cells and decrease of CD8+CD28+ T cells with improvement of cGVHD indicate that these factors may be involved in the development of chronic GVHD and that MSC suppresses chronic GVHD via modulation of the ratios of CD8+CD28- to CD8+CD28+ T cells. However, further immunological studies specifically addressing this issue are needed to confirm this possibility. This work was supported by Science and Technology Planning Project of Guangdong Province (2006B36005003,2007A032100003) and Science and Technology Planning Project of Guangzhou (2006Z2-E4071,2008A1-E4011-4,2008A1-E4011-5). Disclosures: No relevant conflicts of interest to declare.

Phenotypical and Functional Characterization of Bone Marrow Mesenchymal Stem Cells in Patients with Chronic Graft-Versus-host Disease.

Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant.

CXCR4-transduced Mesenchymal Stem Cells Protect Mice Against Graft-Versus-host Disease.

Mesenchymal Stem Cells ameliorate Chronic GVHD by Boosting Thymic Regeneration in a CCR9-dependent manner in mice

Alteration of Naïve and Memory B-cell Subset in Chronic Graft-Versus-host Disease Patients after Treatment with Mesenchymal Stromal Cells.

Mesenchymal Stem Cells Relieve Chronic GVHD Via Modulation the Ratio of CD8+CD28-/CD8+CD28+T Cells.

Phase Ii Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease after Hla-Haploidentical Stem-Cell Transplantation

Mesenchymal Stromal Cells Ameliorate Chronic GVHD by Boosting Thymic Regeneration in a CCR9-dependent Manner in Mice.

A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD

Mesenchymal Stromal Cells Infusions Improve Refractory Chronic Graft Versus Host Disease Through an Increase of CD5+ Regulatory B Cells Producing Interleukin 10

Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Sclerodermatous Chronic Graft-versus-Host Disease: Clinical Report

Immunologic Effects of Mesenchymal Stem Cells in the Treatment of Refractory Acute Graft-Versus-Host Disease

Immunomodulatory Effects of Mesenchymal Stem Cells Involved in Favoring Type 2 T Cell Subsets

Immunomodulation Effects of Mesenchymal Stromal Cells on Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation

Study on the Distribution and Clonal Expansion of TCR Vβ Subfamily in Peripheral T Cells after Infusing Mesenchymal Stem Cells in Patients with Chronic GVHD

The Effect of Mesenchymal Stem Cells on Preventing Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation—the Effect of Mesenchymal Stem Cells on Active T Lymphocytes(in Vitro)

Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

Efficacy and Safety of Mesenchymal Stem Cells Treatment for Multidrug-Resistant Graft-Versus-host Disease after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Efficacy of Umbilical Cord-Derived Menchymal Stem Cell Treatment of Refractory Chronic Graft-Versus-host Disease